ASCO 2026: Strong Momentum for Sarcoma Research

⭐ The phase III SARC041 trial in dedifferentiated liposarcoma met its primary endpoint, demonstrating a significant progression-free survival benefit with abemaciclib. The study was also selected for presentation in the ASCO Plenary Session—an uncommon distinction for a sarcoma trial.
🎯 Important advances in GIST, including positive phase III results for bezuclastinib plus sunitinib and encouraging data for the investigational KIT inhibitor velzatinib.
📈 The phase III RINGSIDE trial in desmoid tumors showed a substantial reduction in the risk of disease progression and further supports gamma-secretase inhibition as a treatment strategy.
🧬 New data in rare sarcoma subtypes—including alveolar soft part sarcoma, clear cell sarcoma, and conventional chondrosarcoma—highlighted continued efforts to expand treatment options in underserved diseases.
🔬 Updated results for engineered T-cell therapy (afami-cel) demonstrated durable activity in selected patients with synovial sarcoma and myxoid/round cell liposarcoma.
🩸 Research on biomarkers and tumor biology, including circulating tumor DNA (ctDNA), provided additional insights into more personalized approaches to sarcoma care.